ADAM17 (a disintegrin and metalloproteinase 17, also referred to as TNFa converting enzyme or TACE) is a cell-surface metalloproteinase that regulates signaling via the epidermal growth factor receptor (EGFR) and has important roles in diseases such as cancer and rheumatoid arthritis. ADAM17 can be activated by stimulation of several tyrosine kinase receptors, raising questions about whether oncogenic tyrosine kinases could also enhance EGFR signaling and activation of extracellular signalregulated kinase (ERK) via stimulation of ADAM17. The main goal of this study was to evaluate the role of Src in activating ADAM17. We provide evidence that a constitutively active transforming form of Src, the E378G mutant, as well as v-Src enhance ADAM17-mediated shedding of the EGFR ligand TGFa. Moreover, we demonstrate that constitutive shedding of TGFa can be reduced by inhibition of Src in several cell lines, including COS7, MCF7 (the human breast cancer cell line), PAE (a pig aortic endothelial cell line) and HaCaT (the human keratinocyte cell line) cells. Src(E378G)-stimulated shedding of TGFa is abolished in Adam17 À/À cells, but can be rescued by wild-type (wt) ADAM17 and a mutant ADAM17 lacking its cytoplasmic domain. These findings demonstrate that ADAM17 is the principal TGFa sheddase that is activated by Src in a manner that does not require the cytoplasmic domain of ADAM17. Finally, we show that stimulation of ADAM17 by Src(E378G) leads to enhanced paracrine signaling via release of EGFR ligands into the culture supernatant. These results raise the possibility that activation of ADAM17 by oncogenic forms of Src can aid in promoting tumorigenesis by enhancing signaling via the EGFR and ERK in an autocrine and paracrine manner. Enhanced autocrine signaling could further activate tumor cells expressing oncogenic mutants of Src, whereas paracrine signaling could stimulate EGFR and ERK signaling in surrounding non-transformed cells such as stromal cells, thereby contributing to crosstalk between tumor cells and stromal cells.
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Keywords: ADAM17; Src; EGF receptor; EGFreceptor ligands; protein ectodomain shedding; ERK Cell-cell interactions are critical for the development and maintenance of an adult organism, but they can also contribute to pathologies such as cancer when they become dysregulated. Membrane-anchored metalloproteinases have emerged as key regulators of cell-cell interactions, because of their ability to cleave and release growth factors, cytokines and various other membrane proteins in a process referred to as protein ectodomain shedding (Blobel, 2005; Murphy, 2008) . The membraneanchored metalloproteinase ADAM17 (a disintegrin and metalloproteinase 17, also referred to as TNFa converting enzyme or TACE) is considered a principal sheddase for many membrane proteins, and is essential for regulating the bioavailability of ligands of the epidermal growth factor (EGF) receptor such as TGFa and HB-EGF, and of soluble TNFa (Peschon et al., 1998; Sunnarborg et al., 2002; Sahin et al., 2004; Horiuchi et al., 2007a, b) . Recently, stimulation of the tyrosine kinase receptor VEGF receptor-2 was shown to activate ADAM17, but not ADAM10, via the extracellular signal-regulated kinase (ERK) and mitogenactivated protein kinase pathways (Swendeman et al., 2008) . In addition, ADAM17 can be activated by several other cellular signaling pathways, including G-proteincoupled receptors (Prenzel et al., 1999; Fischer et al., 2003) and LPS-induced septic shock (Horiuchi et al., 2007a) .
The ability of various cellular signaling pathways to activate ADAM17 raises questions about the potential role of oncogenic tyrosine kinases in stimulating ADAM17, and whether this could enhance autocrine and paracrine signaling via the release of ligands of the EGFR. Previous studies have provided evidence for a role of Src family kinases in the activation of ADAM17 (Zhang et al., 2006; Van Schaeybroeck et al., 2008) . In addition, Src has been reported to associate with ADAM17, and this is accompanied by phosphorylation of Src and ADAM17 and their translocation to the cell membrane. As ADAM17 has been implicated in the progression of different types of cancer (Tanaka et al., 2005; Zhou et al., 2006; McGowan et al., 2008) , the goal of this study was to determine whether the transforming mutants of Src could enhance the activity of ADAM17, as this could be a pathologically relevant aspect of the mechanism underlying oncogenic transformation of cells by Src.
To evaluate the role of a transforming Src kinase in regulating the catalytic activity of ADAM17, we tested whether the constitutively active Src mutant Src(E378G) (Levy et al., 1986) stimulated the shedding of the ADAM17 substrate TGFa in cell-based assays. We first compared how the transforming Src(E378G) or the inactive mutant Src(K295A) (Levy et al., 1986; Ma et al., 2000) affected the cell-associated levels of the alkaline phosphatase (AP)-tagged form of the ADAM17 substrate TGFa (Sahin et al., 2004; Horiuchi et al., 2007b) in mouse embryonic fibroblasts (mEFs). When Src(E378G) was co-transfected with TGFa, we observed depletion of TGFa in the cell lysates compared with cells coexpressing TGFa and the inactive Src(K295A) as a control ( Supplementary Figures 1b and d) prevented the depletion of TGFa-AP in cells expressing Src(E378G), suggesting that the depletion of TGFa depended both on the mutant Src and on a metalloproteinase, most likely ADAM17. When we evaluated the release of TGFa into the culture supernatant of cells that were co-transfected with Src(E378G) or v-Src, we observed an approximately twofold increase of TGFa shedding compared with cells coexpressing the inactive Src(K295A) or MAD2, used here as an additional control ( Figure 1c ). In these experiments, cells were preincubated with 5 mM Marimastat overnight to normalize the levels of TGFa at the outset of this experiment (see Figure 1b) , and then the Marimastat was washed out in order to monitor the shedding of TGFa over 4 h following washout. These results suggest that ADAM17 was significantly more active under the influence of the transforming variants of Src (Src(E378G) or v-Src compared with the two controls (Src(K295A) and MAD2). However, Src(E378G) or v-Src did not stimulate shedding of the ADAM10 substrate betacellulin (BTC) (Sahin et al., 2004; Horiuchi et al., 2007b) when compared with the inactive Src(K295A) or MAD2 (Figure 1d ), so Src(E378G) appeared to activate ADAM17, but not ADAM10. Because v-Src and the constitutively active Src(E378G) stimulated ADAM17 to a similar extent, we focused on characterizing the effects of Src(E378G) on ADAM17 for the remainder of this study. When we tested whether Src(E378G) also increased the shedding of other substrates of ADAM17 following pre-incubation and washout of Marimastat as described above, we found that it stimulated the shedding of ICAM-1, amphiregulin and TNFa, all of which have been characterized as substrates of ADAM17 (Sahin et al., 2004; Horiuchi et al., 2007a; Weskamp et al., 2010) (Figure 1e ). Taken together, these results demonstrate that two transforming mutant forms of Src, Src(E378G) and v-Src, significantly stimulate ADAM17, as evidenced by the increased shedding of TGFa and other substrates of ADAM17.
To determine whether endogenous Src has a role in the constitutive activity of ADAM17, we tested whether Src-kinase inhibitors affected the release of TGFa from COS7 cells as well as other cell types. As shown in Figures 2a-c , addition of the Src-kinase family inhibitors PP1 (Biomol, Plymouth Meeting, PA, USA), PP2 or Desatinib (kindly provided by Mark Moasser UCSF Medical Center, San Francisco, CA, USA) reduced shedding of the ADAM17 substrate TGFa in a dosedependent manner. However, the constitutive shedding of the ADAM10 substrate BTC was not significantly affected by 10 mM PP1 or PP2, and was only slightly decreased by Desatinib, demonstrating that the constitutive activity of ADAM10 did not depend on Src or related family members. The structurally similar but inactive PP3 (Calbiochem, San Diego, CA, USA) did not influence the activity of ADAM17 or ADAM10 ( Figure 2d ). Similar results were obtained with three different cell lines, MCF7 (the human breast cancer cell line), PAE (a pig aortic endothelial cell line) and HaCaT (the human keratinocyte cell line). In all three cell lines, 10 mM Desatinib blocked shedding of transfected TGFa by B50%, whereas the inactive PP3 had no significant effect ( Figure 2e ). Importantly, we found that treatment with 10 mM Desatinib did not reduce shedding of TGFa from Src À/À cells, which corroborates the selectivity of this reagent (Figure 2e ). In addition, Desatinib also blocked the release of other AP-tagged ADAM17 substrates from COS7 cells, including ICAM-1, TNFa and amphiregulin ( Figure 2f ). When we tested whether Desatinib blocks the shedding of TGFa in the presence of various stimuli, we found that it reduced VEGFstimulated shedding of TGFa from PAE cells, but did not affect thrombin-stimulated shedding, and only weakly affected PMA-stimulated shedding of TGFa . Desatinib also had no effect on shedding of BTC following stimulation with ionomycin ( Supplementary Figure 2d) .
To corroborate that ADAM17 is critical for the Srcstimulated shedding of TGFa, we performed rescue experiments in Adam17 À/À mEFs (Horiuchi et al., 2007a) . The low amount of shedding of TGFa from Adam17 À/À cells transfected with the catalytically inactive ADAM17E4A mutant and MAD2, Src(K295A) or Src(E378G) was significantly increased when these cells were rescued by co-transfection with wild-type (wt) ADAM17. More importantly, the constitutively active Src(E378G) further increased TGFa shedding in cells rescued with wt ADAM17 compared with MAD2 or Src(K295A) (Figure 3a) . Furthermore, we found that the increased constitutive shedding of TGFa from cells expressing ADAM17 was sensitive to treatment with the Src-family inhibitors PP2 and Desatinib as well as the hydroxamate Marimastat, whereas none of these compounds significantly affected the low levels of background shedding of TGFa from Adam17 À/À cells expressing the inactive ADAM17E4A mutant (Figure 3b) . Immortalized wt mEFs on six-well plates were transiently transfected with an AP-tagged TGFa and the inactive Src(K295A) or the constitutively active Src(E378G) (Levy et al., 1986; Ma et al., 2000; Sun et al., 2007) . At 6 h after transfection, the cells were incubated with the Src inhibitor PP2 (10 mM) (a) or the metalloproteinase inhibitor Marimastat (5 mM) (b) for 8 h. Cells were lysed on ice in TBS Triton X-100 (1%), 1 mmol/l EDTA and glycoproteins were precipitated with the lectin Con-A overnight and eluted the next day with 0.5 mM methyl a-D manno-pyranoside. All reagents were from Sigma-Aldrich (St Louis, MO, USA) unless otherwise indicated. For the evaluation of the AP activity in the cell lysates, equal amounts of total protein were separated by 8% SDS-PAGE and then incubated with NBT/BCIP (Roche, San Francisco, CA, USA) substrate solution for 10 min (Sahin et al., 2006) . Cells expressing Src(E378G) showed strongly decreased levels of TGFa in comparison with cells transfected with Src(K295A). The expression of TGFa in cells co-transfected with Src(E378G) could be restored by incubation with PP2 (a) or Marimastat (b).
(c, d) Shedding of TGFa (c) or betacellulin (BTC) (d) into the supernatant of wt mEFs was analyzed by colorimetric assay for AP activity. For photometric quantitation of AP activity in the culture supernatant, 100 ml of conditioned medium was mixed with 100 ml of a 2 mg/ml solution of the AP substrate 4-nitrophenyl phosphate in 100 mM Tris-HCl, pH 9.5, 100 mM NaCl, 20 mM MgCl 2 . After incubation at 37 1C for 30 min, the amount of product was quantitated by determining the A 405 . The shedding of TGFa into the supernatant of mEFs was enhanced by co-transfection of Src(E378G) and v-Src compared with co-transfection by the inactive Src(K295A) or MAD2, used as a control. (d) The shedding of BTC, used here as a readout for the activity of ADAM10 (Sahin et al., 2004) , was not affected by the co-expression of Src(E378G) or v-Src compared with Src(K295A) or MAD2. (e) When we compared shedding of the ADAM17 substrates ICAM-1 (Weskamp et al., 2010) , amphiregulin (Sahin et al., 2004) or TNFa (Black et al., 1997; Moss et al., 1997; Horiuchi et al., 2007a) in the presence of Src(K295A) or Src(E378G), we found that the transforming form of Src increased the shedding of all the three ADAM17 substrates. The results were obtained from three independent experiments and expressed as means±s.e.m. Pairwise comparison was performed by Mann-Whitney rank-sum test, multiple comparisons versus a control group by Dunnett's method using SigmaStat 3.1 software (SYSTAT, Erkrath, Germany). P-values o0.05 were considered statistically significant, and samples with significant changes compared with controls are marked by an asterisk.
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Previous studies have implicated phosphorylation of the cytoplasmic domain of ADAM17 in its response to activation by gastrin-dependent peptide and Src (Zhang et al., 2006) . Here we found that a mutant form of ADAM17 with an intact transmembrane domain but lacking a cytoplasmic domain (ADAM17-Wcyto) (Le Gall et al., 2009) could rescue the shedding of TGFa from Adam17 À/À cells as well as wt ADAM17, and that its activity could be further enhanced by Src(E378G) (Figure 3c ). In addition, the increased shedding of TGFa from Adam17
À/À cells rescued with ADAM17-Wcyto could be inhibited with PP2, Desatinib and Marimastat to a similar degree as in Adam17
À/À cells rescued with wt ADAM17 when compared with untreated cells or cells treated with the inactive PP3 (Figure 3d ). These results demonstrate that the Srcstimulated TGFa shedding is independent of phosphorylation of the ADAM17 cytoplasmic tail, which is consistent with previous reports that the activation of ADAM17 by phorbol 12-myristate 13-acetate also does not depend on the presence of its cytoplasmic domain ( at concentrations between 1 and 10 mM, as indicated, whereas shedding of the ADAM10 substrate BTC was not affected by 10 mM PP1, 2 or 3, and was only weakly reduced by Desatinib at 10 mM (a-d). (e) Treatment of other cell lines with 10 mM Desatinib also reduced shedding of transfected TGFa, whereas treatment with the inactive PP3 did not (MCF7 breast cancer cells, ATCC, PAE-KDR porcine aortic endothelial cells expressing the human VEGFR2/KDR, referred to as PAE cells throughout, provided by Dr S Rafii, Weill Cornell University, New York, and the HaCaT human keratinocyte cell line, kindly provided by Dr T Ludwig, Columbia University, New York). Similar experiments with Src À/À cells showed no effect of Desatinib in the absence of Src. (f) Shedding of the AP-tagged ADAM17 substrates ICAM-1, amphiregulin and TNFa from COS7 cells could also be reduced by Desatinib. All results were obtained from three independent experiments and expressed as means±s.e.m. Pairwise comparisons were performed by Mann-Whitney ranksum test, multiple comparisons versus a control group by Dunnett's method, all pairwise multiple comparison procedures by Tukey's test using SigmaStat 3.1 software. P-values o0.05 were classified as statistically significant, and the corresponding samples are marked by an asterisk.
To corroborate that ADAM17 is also responsible for Src-dependent shedding in the other cell lines tested herein, we assessed the ability of the ADAM17-selective hydroxamate inhibitors SP26 (Mazzola et al., 2008) and DPC333 (Qian et al., 2007) to block the shedding of TGFa from MCF7, HaCaT, PAE and Src À/À cells at concentrations at which these inhibitors block ADAM17, with little or no effect on ADAM10 (2.5 mM SP26, 0.25 mM DPC333; see Supplementary Figures 3a-d for titration curves of SP26 and DPC333 in cell-based assays in COS7 cells). At these concentrations, both inhibitors blocked the shedding of TGFa in all four cell lines, whereas they did not affect shedding of the ADAM10 substrate BTC, corroborating that shedding of TGFa also depends on ADAM17 in these cell lines (Supplementary Figures 3g-n) . As an additional control, we demonstrated that the ADAM10 selective inhibitor GI254023X (Hundhausen et al., 2003) did not significantly affect the stimulation of TGFa shedding by Src(E378G), even though it strongly reduced shedding of BTC in all cell lines tested here at a concentration of 1 mM (the titration curve for GI254023X in cell-based assays is shown in Supplementary Figures 3e and f) . Moreover, treatment of the two human cell lines HaCaT and MCF7 with small interfering RNA (siRNA) against human ADAM17 strongly reduced the expression of ADAM17 and the shedding of TGFa ( Supplementary  Figures 4a and b) . Finally, to rule out the contribution of other ADAMs to Src(E378G)-stimulated shedding of TGFa in mEFs, we tested how lack of ADAM8, À/À cells transfected with TGFa and either wt ADAM17 or the inactive ADAME4A were treated with 10 mM of PP3, PP2 or Desatinib or 5 mM Marimastat. All inhibitors were pre-incubated for 10 min, and AP activity in the supernatants (conditioned for 2 h) and cell lysates was measured by colorimetry (Sahin et al., 2006) . The effect of PP2, Desatinib and Marimastat depended on the presence of ADAM17. (c) Shedding of TGFa from Adam17 À/À cells coexpressing inactive ADAM17E4A or the cytoplasmic deletion mutant of ADAM17 (ADAM17-Wcyto) (Le Gall et al., 2009) , and Src(K295A) or Src(E378G). The activation of ADAM17 by Src(E378G) did not require the cytoplasmic domain of ADAM17. (d) Adam17
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À/À cells rescued with either wt ADAM17 or ADAM17-Wcyto were treated with or without 10 mM of PP3 or PP2, Desatinib or 5 mM Marimastat. The effect of these inhibitors on TGFa shedding also did not depend on the presence of the cytoplasmic domain of ADAM17. Results were obtained from three independent experiments and are expressed as means±s.e.m. All pairwise multiple comparison procedures were performed by Tukey's test using SigmaStat 3.1 software. (a, c) þ P-value o0.05 with respect to the effect of ADAM17 or ADAM17-Wcyto on the shedding of TGFa compared with ADAM17E4A. *P-value o0.05 for the effect of Src(E378G) compared with Src(K295A) on the shedding of TGFa by overexpressed ADAM17. (b, d) *P-value o0.05 for the effect of ADAM17 or ADAM17-Wcyto on the shedding of TGFa relative to ADAM17E4A, and þ P-value of o0.05 for the effect of Src kinase inhibitors PP2 or Desatinib or the metalloprotease inhibitor Marimastat on the shedding of TGFa compared with untreated cells.
Oncogenic Src activates ADAM17 T Maretzky et al ADAM9/12/15, ADAM10, ADAM17 or ADAM19 affected the activation of TGFa shedding by Src(E378G). We found no difference in the Src(E378G)-dependent stimulation of TGFa shedding in Adam8
À/À or Adam19 À/À mEF cells compared with wt controls (Supplementary Figure 4c) , whereas constitutive shedding of TGFa was strongly reduced in Adam17 À/À cells, with no further stimulation by cotransfection with Src(E378G). Taken together, these results corroborate that Src kinases have an important role in mediating the constitutive release of substrates of ADAM17, but not of ADAM10 substrates. In addition, the use of ADAM17-selective inhibitors and siRNA as well as mEFs from mice lacking other widely expressed and catalytically active ADAMs supports the interpretation that ADAM17 is the main sheddase that responds to activation by endogenous Src and the transforming mutant Src(E378G).
ADAM17 is essential for activating the EGFR during mouse development (Peschon et al., 1998; Jackson et al., 2003; Blobel, 2005; Sternlicht et al., 2005) , and the release of EGFR ligands by ADAM17 is known to promote tumor progression (Blanchot-Jossic et al., 2005; Zhou et al., 2006; Merchant et al., 2008 ; T Maretzky et al Nakagawa et al., 2009) . To determine whether Src (E378G) could affect paracrine EGFR/ERK activation via stimulation of ADAM17, we collected supernatants from COS7 cells transfected with Src(E378G) or the inactive Src(K295A), and then added these conditioned supernatants to serum-starved A431 human carcinoma cells, which express high levels of the EGFR/ ErbB1 (Cooper et al., 1983) . A western blot analysis revealed increased phosphorylation of the EGFR as well as Akt and ERK1/2 in extracts of A431 cells treated with conditioned medium from COS7 cells overexpressing Src(E378G) compared with supernatants from COS7 cells transfected with Src(K295A) (Figure 4a ). The increased phosphorylation of ERK1/2 by supernatants from COS7 cells expressing Src(E378G) could be blocked if the supernatants were conditioned in the presence of 5 mM Marimastat (data not shown) or the ADAM17-selective inhibitor SP26 (Figure 4a ). In addition, the phosphorylation of EGFR, Akt and ERK in A431 cells in response to adding conditioned media from Src(E378G)-expressing COS7 cells could be completely prevented by the EGFR-selective tyrosine kinase inhibitor AG1478 (Figure 4b ). These results are consistent with a model in which Src(E378G) stimulates ADAM17 to release ligands of the EGFR from COS7 cells, which are then able to activate the EGFR in A431 cells in a paracrine manner. Overexpression of EGFR ligands and inappropriate activation of the EGFR are known to contribute to tumorigenesis (Yarden and Sliwkowski, 2001; Zhou et al., 2006) , and the increased stimulation of ADAM17 and release of EGFR ligands by an activated form of Src is likely to also cause activation of ERK signaling in cells that do not express the mutant Src oncogene. Thus, ADAM17 could function to exacerbate Src-dependent transformation and tumorigenesis by producing soluble EGFR ligands that enhance paracrine EGFR signaling on adjacent non-transformed cells. The increased stimulation of these cells by EGFR ligands could aid in their transformation, and could be an important component of the interactions between tumor cells and stromal cells, which are known to make critical contributions to tumorigenesis (Egeblad et al., 2005; Page-McCaw et al., 2007) . In summary, this study provides the first evidence, to our knowledge, that a transforming mutant form of Src can stimulate the catalytic activity of ADAM17. Our findings suggest that activated forms of Src might stimulate the EGFR and ERK in the Src-expressing tumor cells as well as in surrounding non-transformed stromal cells by activation of ADAM17 and release of ligands of the EGFR. ADAM17 has been implicated in the proliferation and invasion of tumor cells (Tanaka et al., 2005; Zhou et al., 2006; McGowan et al., 2008) , so its dysregulation by oncogenic mutant Src could have an important role during cancer development. Furthermore, these results suggest that inhibitors of ADAM17 might be useful for treating cancers in which the function of ADAM17 is dysregulated by activating mutations in Src.
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The authors declare no conflict of interest. Figure 4 Supernatants from COS7 cells expressing the transforming mutant Src(E378G) can activate the EGFR and ERK in A431 cells. (a, b) COS7 cells on 10-cm plates were transiently transfected with either Src(K295A) or Src(E378G) and incubated in the presence or absence of 2.5 mM of the ADAM17-selective hydroxamate inhibitor SP26 (a) for 4 h in Optimem medium. A volume of 5 ml of these conditioned supernatants was removed and incubated for 10 min with A431 cells, a cell line that expresses high levels of the EGFR/ErbB1 (Cooper et al., 1983) . The A431 cells had been serum-starved overnight before the addition of the conditioned supernatants from COS7 cells. For the experiments with the EGFR tyrosine kinase inhibitor AG1478 shown in panel b, 0.5 mM AG1478 was pre-incubated with A431 cells for 10 min in Optimem before adding the conditioned media from COS7 cells, which was adjusted to 0.5 mM AG1478 as indicated. The A431 cells were then lysed on ice in TBS Triton X-100 (1%), 1 mmol/l EDTA and protease inhibitor cocktail (Roche, San Francisco, CA, USA). Identical amounts of protein were separated on 10% SDS-polyacrylamide gels and transferred onto polyvinylidene difluoride membranes (BioTrace, Pall Corporation, Ann Arbor, MI, USA). Membranes were blocked in 5% skim milk in TBS, incubated with rabbit anti-phospho-EGFR or anti-total EGFR, antiphospho-Akt, rabbit anti-phosphoERK1/2 antibodies (Cell Signaling Technology, Danvers, MA, USA) or anti-total-ERK2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and then with peroxidase-conjugated goat anti-rabbit secondary antibody (Promega, Madison, WI, USA), and bound antibodies were visualized using the enhanced chemiluminescence detection system (Amersham Biosciences, Piscataway, NJ, USA) and a Chemdoc image analyzer (Bio-Rad, Hercules, CA, USA). One representative out of three immunoblots with essentially identical results is shown in a and b. Supernatants from COS7 cells expressing Src(E378G) activated ERK1/2 more strongly than supernatants from COS7 cells expressing Src(K295A), and this activation depended on a metalloproteinase, most likely ADAM17, in COS7 cells, and on activation of the EGFR and Akt in A431 cells. (c-h) The results of densitometric quantification of western blots from three separate experiments ± s.e.m. show how treatment with 2.5 mM SP26 (c, e, g) or 0.5 mM AG1478 (d, f, h) affected the phosphorylation of the EGFR (c, d), Akt (e, f) or ERK1/2 (g, h). All pairwise multiple comparison procedures were performed by Tukey's test using SigmaStat 3.1 software. *P-value o0.05 for the effect of Src(E378G) on the phosphorylation of the EGFR, Akt or ERK1/2 compared with the effect of Src(K295A).
þ P-value o0.05 for the effect of SP26 on the phosphorylation of ERK1/2 by overexpressed Src(E378G). # P-value o0.05 for the effect of AG1478 on phosphorylation of the EGFR, Akt or ERK1/2 by overexpressed SRC(K295A) or Src(E378G), respectively.
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